Cedra names two new directors

They join business development in generics and automation for the bioanalytical division

Cedra Corporation, a division of Worldwide Clinical Trials and provider of Phase I-IIb clinical research and bioanalytical services, has appointed John Pottier as senior director of business development in generics and Thomas Lloyd as director of automation for the Bioanalytical Group.

Pottier has more than 17 years within the sales and marketing sector of the contract research organisation (CRO) market.

Prior to joining Cedra, Pottier held positions with Novum Pharmaceutical Research Services and PRACS Institute/Cetero Research relating to business development.

Lloyd has more than 22 years of experience in developing and automating analytical and bioanalytical processes. His specific expertise is in automation systems and analytical instrument development, bioanalytical chemistry, in vitro DMPK studies, software programming and application, statistics, chemometrics and GLP requirements.

Prior to joining Cedra, Lloyd led the automation group at Pfizer, previously known as Wyeth Research. He has held previous positions at DuPont Merck Pharmaceutical Company and Glaxo.

You may also like

Drug Delivery

MetP Pharma unveils brain-targeted intranasal GLP-1 delivery technology

Preclinical data shows the company's proprietary nose-to-brain technology enables rapid, dose-dependent brain targeting of intranasal semaglutide with low systemic exposure, opening new opportunities for CNS-focused GLP-1 therapies
Research & Development

EMBO Installation Grant supports new genome editing lab at Vilnius University

Dr C. Patinios Awarded EMBO Installation Grant to advance genome editing research in Lithuania
Research & Development

Merck and Moderna announce 5-year data for intismeran autogene in combination with KEYTRUDA

Eight Phase II and Phase III clinical trials are under way across multiple tumour types, including melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma
Manufacturing

Cellistic launches new iPSC-based GMP platforms to boost cell therapy development

Echo-T, Echo-Cardio, and Echo-Endothelial enable scalable immuno-oncology and regenerative therapies
Regulatory

3PBIOVIAN secures French CIR certification for Spain and Finland R&D sites

The CDMO has obtained French Crédit d’Impôt Recherche (CIR) certification for its Pamplona and Turku sites, enabling French partners to access tax incentives when collaborating on recombinant protein and advanced therapy projects
Research & Development

FDA and EMA issue guiding principles for AI in drug development

The set of ten principles gives broad guidance on AI use in evidence generation and monitoring across all phases of a medicine, from early research and clinical trials to manufacturing and safety monitoring
Drug Delivery

Bio-Sourcing and Zerion Pharma secure Eurostars funding to develop HER2 oral monoclonal antibody

The pair have been awarded a €1.3m Eurostars grant to develop an oral formulation of the anti-HER2 monoclonal antibody trastuzumab for breast cancer, combining Bio-Sourcing’s BioMilk platform with Zerion’s Dispersome technology to advance the candidate through preclinical development
Subscribe now